BioProspect's Termilone nears approval submission
The Australian biotechnology company, BioProspect (Perth, Western Australia), expects to submit an Australian approval application for its eremophilone oil-based termiticide, Termilone, by September. A mammalian dermal toxicity study has shown that the product has “no toxicity”, the company says. It will carry out an acute inhalation study over the next three months before making its approval application. BioProspect will continue to work with collaborators on the development of commercial products as part of the Termilone range.